From Bench to Bedside: Immunotherapy for Prostate Cancer
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168152/ |